Your browser doesn't support javascript.
loading
Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
Murji, Amyn A; Qin, Juliana S; Hermanus, Tandile; Morris, Lynn; Georgiev, Ivelin S.
Afiliación
  • Murji AA; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Qin JS; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Hermanus T; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Morris L; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
  • Georgiev IS; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg 2131, South Africa.
Viruses ; 13(7)2021 07 02.
Article en En | MEDLINE | ID: mdl-34372503
A leading strategy for developing a prophylactic HIV-1 vaccine is the elicitation of antibodies that can neutralize a large fraction of circulating HIV-1 variants. However, a major challenge that has limited the effectiveness of current vaccine candidates is the extensive global diversity of the HIV-1 envelope protein (Env), the sole target for HIV-neutralizing antibodies. To address this challenge, various strategies incorporating Env diversity into the vaccine formulation have been proposed. Here, we assessed the potential of two such strategies that utilize a nanoparticle-based vaccine platform to elicit broadly neutralizing antibody responses. The nanoparticle immunogens developed here consisted of different formulations of Envs from strains BG505 (clade A) and CZA97 (clade C), attached to the N-termini of bacterial ferritin. Single-antigen nanoparticle cocktails, as well as mosaic nanoparticles bearing both Env trimers, elicited high antibody titers in mice and guinea pigs. Furthermore, serum from guinea pigs immunized with nanoparticle immunogens achieved autologous, and in some cases heterologous, tier 2 neutralization, although significant differences between mosaic and single-antigen nanoparticles were not observed. These results provide insights into the ability of different vaccine strategies for incorporating Env sequence diversity to elicit neutralizing antibodies, with implications for the development of broadly protective HIV-1 vaccines.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Vacunas contra el SIDA / Nanopartículas / Productos del Gen env del Virus de la Inmunodeficiencia Humana / Anticuerpos Neutralizantes Límite: Animals Idioma: En Revista: Viruses Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Infecciones por VIH / VIH-1 / Vacunas contra el SIDA / Nanopartículas / Productos del Gen env del Virus de la Inmunodeficiencia Humana / Anticuerpos Neutralizantes Límite: Animals Idioma: En Revista: Viruses Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza